Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

Inclusion Criteria:

Healthy volunteers [for Study Aim 1 (SA1) and Study Aim 2 (SA2)] will be entered into the study if they meet the following criteria:

• Age ≥ 18 years
• Able to understand and give informed consent
• No known cancer diagnosis

Patients [for Study Aim 1 (SA1)] will be entered into the study if they meet the following criteria:

• Age ≥ 18 years
• Able to understand and give informed consent
• At least one untreated brain metastasis > 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)

Patients [for Study Aim 3 (SA3)] will be entered into the study if they meet the following criteria:

• Age ≥ 18 years
• Able to understand and give informed consent
• At least one untreated brain metastasis > 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
• Planned SRS treatment

Exclusion Criteria:

Healthy volunteers (SA1 & SA2) and patients (SA1 & SA3) exclusion criteria:

• Pregnant or breastfeeding women
• Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
• Age < 18 years